Alliance Pharma (LSE:APH) Debt-to-Asset : 0.26 (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Debt-to-Asset?

Alliance Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was £0.6 Mil. Alliance Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was £95.1 Mil. Alliance Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was £369.1 Mil. Alliance Pharma's debt to asset for the quarter that ended in Dec. 2024 was 0.26.

Alliance Pharma Debt-to-Asset Historical Data

The historical data trend for Alliance Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Debt-to-Asset Chart

Alliance Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.28

0.24

0.27

0.28

0.26

Alliance Pharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.27	0.24	0.28	0.27	0.26

Competitive Comparison of Alliance Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alliance Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Alliance Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alliance Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.596	+	95.1)	/	369.139
	=	0.26

Alliance Pharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.596	+	95.1)	/	369.139
	=	0.26

Alliance Pharma (LSE:APH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alliance Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).